The Evidence is in, Cannabis Can Reduce Prescription Opioid Use
Credit: ashton on Wikimedia Commons
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
A new study suggests that smoking cannabis may lower the number of prescription opioids needed to produce pain relief.
The findings were published in Neuropsychopharmacology on February 20, 2018.
“Clinicians are looking for strategies to decrease opioid use to the lowest possible dose while still ensuring adequate pain relief,” said Ziva Cooper, PhD, associate professor of clinical neurobiology (in psychiatry) at the Columbia University Vagelos College of Physicians and Surgeons and lead author of the study.
Previous studies, in animal models, have suggested that cannabis may decrease the amount of opioid medication needed for pain relief. But the combination hasn’t been studied under controlled conditions in humans.
For this placebo-controlled, double-blind study, 18 regular cannabis smokers were given either 2.5 mg—half the lowest dose prescribed for pain relief—or 5 mg of oxycodone or placebo while smoking cannabis. They then used a model of pain testing that has predictive validity for analgesics used therapeutically in which a hand is immersed in cold water and removed when the patient begins to feel pain. Pain relief—time until pain was experienced and the amount of time the pain was tolerated before withdrawing the hand—was assessed several times over 3 hours. The participants repeated this experiment six times over the next several weeks, with a different drug combination in each session. They also measured the how the cannabis and opioid combination affected the abuse potential of each drug.
Not surprisingly, the 5 mg opioid dose—the lowest dose prescribed for pain relief—by itself, reduced pain. While the 2.5 mg opioid dose alone did not reduce pain, combining it with active cannabis produced pain relief comparable to the 5 mg dose alone.
No changes in cannabis’s intoxication or abuse potential were detected. However, participants who took low-dose oxycodone and active cannabis were more likely to report positive subjective ratings of oxycodone.
“Findings from observational studies have suggested that problematic prescription opioid use has been greatest among patients with chronic pain,” said Cooper. “Additional studies in chronic pain patients are needed to determine the abuse potential of low-dose oxycodone when combined with cannabis. It is also critical to study the analgesic effects of low-dose oxycodone when combined with forms of cannabis that are not smoked.”
This article has been republished from materials provided by [SOURCE]. Note: material may have been edited for length and content. For further information, please contact the cited source.